CA2703006A1 - Compositions and methods for treating cancer - Google Patents

Compositions and methods for treating cancer Download PDF

Info

Publication number
CA2703006A1
CA2703006A1 CA2703006A CA2703006A CA2703006A1 CA 2703006 A1 CA2703006 A1 CA 2703006A1 CA 2703006 A CA2703006 A CA 2703006A CA 2703006 A CA2703006 A CA 2703006A CA 2703006 A1 CA2703006 A1 CA 2703006A1
Authority
CA
Canada
Prior art keywords
dna
pathway
dnapol
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2703006A
Other languages
English (en)
French (fr)
Inventor
Alan D'andrea
David T. Weaver
Markus Grompe
Richard Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Oregon Health and Science University
DNAR Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2703006A1 publication Critical patent/CA2703006A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
CA2703006A 2006-10-20 2007-10-22 Compositions and methods for treating cancer Abandoned CA2703006A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85320806P 2006-10-20 2006-10-20
US60/853,208 2006-10-20
US89560607P 2007-03-19 2007-03-19
US60/895,606 2007-03-19
PCT/US2007/022439 WO2008066624A2 (en) 2006-10-20 2007-10-22 Dna damage repair inhibitors and methods for treating cancer

Publications (1)

Publication Number Publication Date
CA2703006A1 true CA2703006A1 (en) 2008-06-05

Family

ID=39327045

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2703006A Abandoned CA2703006A1 (en) 2006-10-20 2007-10-22 Compositions and methods for treating cancer

Country Status (6)

Country Link
US (3) US20090062196A1 (https=)
EP (1) EP2092083A2 (https=)
JP (1) JP2010506939A (https=)
AU (1) AU2007325900A1 (https=)
CA (1) CA2703006A1 (https=)
WO (1) WO2008066624A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2092083A2 (en) 2006-10-20 2009-08-26 Dana-Farber Cancer Institute Dna damage repair inhibitors and methods for treating cancer
GB0713192D0 (en) * 2007-07-06 2007-08-15 Vereniging Het Nl Kanker I Anti-tumour methods
US20110028338A1 (en) 2008-04-02 2011-02-03 John Chute Signatures of radiation response
EP2297345A1 (en) * 2008-05-14 2011-03-23 DNAR, Inc Biomarkers for the identification, monitoring, and treatment of head and neck cancer
WO2009144154A1 (en) * 2008-05-30 2009-12-03 Pangaea Biotech, S.A. Methods and reagents for predicting clinical outcome and customizing chemotherapy in lung cancer patients
CN102203295A (zh) * 2008-09-03 2011-09-28 约翰霍普金斯大学 胰腺肿瘤发生的通路及遗传性胰腺癌基因
WO2010089707A1 (en) * 2009-02-04 2010-08-12 Yeda Research And Development Co. Ltd. Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
GB2471065A (en) * 2009-06-10 2010-12-22 Univ Sheffield Modulator of claspin for treatment of cell proliferative disorder
EP2457095A1 (en) * 2009-07-24 2012-05-30 Institut Gustave Roussy Parp and adjuvant cisplatin-based chemotherapy in non-small-cell lung cancer
CA2797719C (en) * 2010-04-30 2019-11-26 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
WO2011143337A1 (en) * 2010-05-11 2011-11-17 On-Q-ity Biomarkers for the identification monitoring and treatment of breast cancer
GB201011367D0 (en) * 2010-07-06 2010-08-18 Medical Res Council Methods
EP2619574B1 (en) 2010-09-15 2020-10-28 Almac Diagnostic Services Limited Molecular test for predicting responsiveness to dna-damage therapeutic agents in individuals having cancer
CA2742342A1 (en) * 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
JP5762103B2 (ja) * 2011-04-13 2015-08-12 国立大学法人滋賀医科大学 頭頸部癌及び食道癌用抗癌剤及び増強剤
CN103890195A (zh) * 2011-09-08 2014-06-25 耶达研究及发展有限公司 用于肺癌的新型风险生物标志物
US8729048B2 (en) 2011-11-22 2014-05-20 Mayo Foundation For Medical Education And Research Methods and materials for assessing responsiveness to PARP inhibitors and platinating agents
WO2013184905A1 (en) 2012-06-06 2013-12-12 Myriad Genetics, Inc. Hereditary cancer genes
US10370712B2 (en) 2012-09-24 2019-08-06 Duke University Signatures of radiation response
EP3052655B1 (en) 2013-09-30 2018-11-07 Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed
WO2015118338A1 (en) * 2014-02-07 2015-08-13 Mission Therapeutics Limited Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways
US9725425B1 (en) 2014-02-25 2017-08-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
US20150344968A1 (en) * 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
EP3172338B1 (en) 2014-07-25 2018-10-31 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting response to dna repair pathway inhibitors in diffuse large b-cell lymphoma
WO2016078660A1 (en) * 2014-11-20 2016-05-26 Københavns Universitet Detecting replication catastrophe in cells
US20210275630A1 (en) * 2016-04-18 2021-09-09 Phoremost Limited Inactivation of dna repair as an anticancer therapy
JP7224185B2 (ja) 2016-05-01 2023-02-17 ゲノム・リサーチ・リミテッド Ｄｎａサンプルを特徴付ける方法
EP3452937B1 (en) 2016-05-01 2025-10-22 Genome Research Limited Method of characterising a dna sample
CA3051590A1 (en) * 2017-01-25 2018-08-02 Indiana University Research And Technology Corporation Prophylaxis and treatment of acute myeloid leukemia
CN107190007B (zh) * 2017-07-11 2021-02-23 信雅生物科技（苏州）有限公司 一种特异性敲减人brcc3基因慢病毒的构建及在肺癌中的应用
EP3700538A4 (en) 2017-10-23 2020-12-02 Mark David Vincent METHODS OF TREATING CANCER AND / OR IMPROVING SUSCEPTIBILITY TO CANCER TREATMENT BY INCREASING THE BURDEN OF TUMOR MUTATIONS OR TUMOR INDELS
US11413288B2 (en) * 2017-11-01 2022-08-16 Dana-Farber Cancer Institute, Inc. Methods of treating cancers
EP3502700A1 (en) * 2017-12-21 2019-06-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods based on the detection of rad51 foci in tumor cells
US11485736B2 (en) 2018-12-20 2022-11-01 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors
EP4516300A3 (en) * 2019-06-14 2025-08-06 Children's Hospital Medical Center Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
EP4006527B1 (en) 2019-07-25 2025-07-16 Seoul Viosys Co., Ltd Light irradiation apparatus comprising led and method of using the same
WO2021209517A1 (en) 2020-04-15 2021-10-21 Centre National De La Recherche Scientifique Prognosis method of acute myeloid leukaemia
KR20230098186A (ko) 2020-10-30 2023-07-03 케이에스큐 세러퓨틱스 인코포레이티드 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도
GB202113610D0 (en) * 2021-09-23 2021-11-10 Francis Crick Institute Ltd Novel method
CN120741580B (zh) * 2025-06-27 2026-03-20 江苏香地化学有限公司 一种用于检测丝裂霉素c的分子印迹比率型工作电极及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000280389A1 (en) * 2001-11-02 2003-05-19 Dana-Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
US8227434B1 (en) * 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
PL2305221T3 (pl) * 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
CA2609751A1 (en) * 2005-05-24 2006-11-30 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
EP2092083A2 (en) 2006-10-20 2009-08-26 Dana-Farber Cancer Institute Dna damage repair inhibitors and methods for treating cancer

Also Published As

Publication number Publication date
US20160152985A1 (en) 2016-06-02
US20200140868A1 (en) 2020-05-07
EP2092083A2 (en) 2009-08-26
US20090062196A1 (en) 2009-03-05
AU2007325900A1 (en) 2008-06-05
US10738310B2 (en) 2020-08-11
WO2008066624A3 (en) 2008-08-14
WO2008066624A2 (en) 2008-06-05
JP2010506939A (ja) 2010-03-04
AU2007325900A8 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
US20200140868A1 (en) Compositions and methods for treating cancer
US20090081237A1 (en) Prognostic, diagnostic, and cancer therapeutic uses of FANCI and FANCI modulating agents
Chen et al. 53BP1 loss rescues embryonic lethality but not genomic instability of BRCA1 total knockout mice
Krastev et al. Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets
Belal et al. Cancer-associated USP28 missense mutations disrupt 53BP1 interaction and p53 stabilization
Di Masi et al. Cancer predisposing mutations in BRCT domains
Yang et al. BRCA1 antibodies matter
Falck Micronuclei in human peripheral lymphocytes-mechanistic origin and use as a biomarker of genotoxic effects in occupational exposure
Sugawara et al. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li‐Fraumeni or Li‐Fraumeni‐like syndrome
JP2001508868A (ja) 細胞ｄｎａ 修復活性の調節に関するアッセイ、剤、治療及び診断
CA3115658A1 (en) Modular expression systems for gene expression and methods of using same
Nikkilä PALB2 and RAP80 genes in hereditary breast cancer predisposition
JP2009039100A (ja) 癌感受性および欠陥のあるｄｎａ修復機構の診断方法および組成物、ならびにそれらを治療するための方法および組成物
Lauffart et al. Evolutionary conserved interaction of TACC2/TACC3 with BARD1 and BRCA1: potential implications for DNA damage response in breast and ovarian cancer
Bose Molecular and functional characterization of ABRAXAS and PALB2 genes in hereditary breast cancer predisposition
Martiníková The role of truncated PPM1D/Wip1 phosphatase in cancer
Nacson A Study of the BRCA1 Coiled-Coil Region in Mouse Development, Tumor Suppression, and Drug Resistance
Bertolini Genetic and cytological analysis of the Spindle Assembly Checkpoint component BUB-3 in DNA damage response
Merigliano Protein phosphatase 2A (PP2A) is required for the maintenance of Drosophila chromosome integrity
Reich The role of inhibitor of apoptosis proteins and XAF1 in the resistance to anti-cancer treatment in brain tumor cells and high-grade gliomas
Peng Regulation and mechanism of NFBD1 and 53BP1 in mediating DNA damage responses
Novak A Multifaceted Approach to Elucidating the Role of BRCA1-and BRCA2-Related Genes in Hereditary Breast Cancer
Wilson Jr Genetic factors affecting radiation sensitivity and genomic stability
Litman Characterization of the BACH1 Helicase in the DNA Damage Response Pathway: a Dissertation
Mantere DNA damage response gene mutations and inherited susceptibility to breast cancer

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20121022